Last $1.67 USD
Change Today 0.00 / 0.00%
Volume 598.6K
LXRX On Other Exchanges
Symbol
Exchange
LXRX is not on other exchanges.
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

lexicon pharmaceuticals inc (LXRX) Snapshot

Open
$1.68
Previous Close
$1.67
Day High
$1.69
Day Low
$1.64
52 Week High
10/1/13 - $3.18
52 Week Low
06/3/14 - $1.25
Market Cap
860.0M
Average Volume 10 Days
1.4M
EPS TTM
$-0.20
Shares Outstanding
514.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LEXICON PHARMACEUTICALS INC (LXRX)

Related News

No related news articles were found.

lexicon pharmaceuticals inc (LXRX) Related Businessweek News

No Related Businessweek News Found

lexicon pharmaceuticals inc (LXRX) Details

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for human disease. Its drug development programs include LX4211, an orally-delivered small molecule compound that has completed two Phase II clinical trials for the treatment of type 2 diabetes patients, as well as an additional clinical trial for the treatment of type 2 diabetes patients with renal impairment; and completing a Phase II clinical trial for the treatment of type 1 diabetes patients. The company also develops telotristat etiprate or LX1032, an orally-delivered small molecule drug candidate, which has completed two Phase II clinical trials and is in a pivotal Phase III clinical trial for the treatment of carcinoid syndrome and ulcerative colitis. In addition, it develops LX1033, an orally-delivered small molecule compound that has completed Phase II clinical trial for the treatment of irritable bowel syndrome; LX2931, an orally-delivered small molecule compound, which has completed Phase II clinical trial for the treatment of rheumatoid arthritis; and LX7101, a topically-delivered small molecule compound that has completed Phase 1 clinical trial for the treatment of glaucoma. Further, the company’s preclinical development programs comprise LX2761, an orally-delivered small molecule compound for the treatment of diabetes. It has drug discovery and development collaborations with Bristol-Myers Squibb Company, Genentech, Inc., and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

149 Employees
Last Reported Date: 03/7/14
Founded in 1995

lexicon pharmaceuticals inc (LXRX) Top Compensated Officers

Co-Founder, Chief Scientific Officer and Exec...
Total Annual Compensation: $406.7K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $391.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $370.0K
Executive Vice President of Pharmaceutical Re...
Total Annual Compensation: $355.8K
Compensation as of Fiscal Year 2013.

lexicon pharmaceuticals inc (LXRX) Key Developments

Lexicon Pharmaceuticals, Inc. Appoints Lonnel Coats as President and Chief Executive Officer

Lexicon Pharmaceuticals, Inc. announced that Lonnel Coats has been appointed president and chief executive officer effective July 7, 2014. Mr. Coats most recently served as president and chief executive officer of Eisai Inc.

Lexicon Pharmaceuticals, Inc. Announces Data from a Clinical Study with LX4211

Lexicon Pharmaceuticals, Inc. has announced data from a clinical study with LX4211, an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2, or SGLT1 and SGLT2, in patients with type 2 diabetes. Results presented from a clinical study showed that LX4211 significantly reduced postprandial glucose levels in type 2 diabetes patients with moderate to severe renal impairment. In a double-blind, randomized, placebo-controlled, parallel-group study with 31 patients, LX4211 provided statistically significant reductions in postprandial glucose in type 2 diabetes patients with moderate to severe renal impairment. In a sub-group analysis of patients with the most advanced renal impairment, defined as those with a glomerular filtration rate of less than 45 ml/min/1.73 m2, LX4211 similarly reduced postprandial glucose as compared to placebo. Exhibiting its inhibition of SGLT1, LX4211 produced significant elevations in both total GLP-1 and active GLP-1 across all patients. There were no serious adverse events and no discontinuations due to adverse events during the study. In an additional presentation at ADA, Lexicon presented data showing that LX4211 improved glycemic control in mice with poorly controlled type 1 diabetes. LX4211 significantly lowered blood glucose levels in both the low dose and high dose groups while reducing the occurrences of hypoglycemia. In addition, LX4211 significantly slowed the rise in HbA1c levels as compared to vehicle-treated mice with poorly controlled type 1 diabetes.

Lexicon Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 09:00 AM

Lexicon Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 09:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Arthur T. Sands, Co-Founder, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LXRX:US $1.67 USD 0.00

LXRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LXRX.
View Industry Companies
 

Industry Analysis

LXRX

Industry Average

Valuation LXRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 401.3x
Price/Book 6.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 346.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LEXICON PHARMACEUTICALS INC, please visit www.lexpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.